Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zongertinib with paclitaxel plus ramucirumab in previously treated HER2-positive gastric, esophageal adenocarcinoma, or gastroesophageal junction cancer
KCT0012881Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of zongertinib, paclitaxel and ramucirumab in gastric cancer (GC), esophageal adenocarcinoma (EAC) and esophagogastric junction cancer (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities and Objective response rate. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
zongertinibpaclitaxelramucirumab
03
Conditions
gastric cancer (GC)esophageal adenocarcinoma (EAC)esophagogastric junction cancer
Beyond the preview
Go deeper on KCT0012881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012881.